临床荟萃 ›› 2024, Vol. 39 ›› Issue (6): 506-511.doi: 10.3969/j.issn.1004-583X.2024.06.004
收稿日期:
2023-12-22
出版日期:
2024-06-20
发布日期:
2024-07-18
通讯作者:
李健,Email:基金资助:
Song Yijing, Li Jian(), Song Qin, Shao Li
Received:
2023-12-22
Online:
2024-06-20
Published:
2024-07-18
Contact:
Li Jian, Email: 摘要:
目的 探讨C-反应蛋白(C-reactive protein CRP)和甘油三酯-葡萄糖(triglyceride glucose TyG)指数对类风湿关节炎(Rheumatoid arthritis RA)人群发生冠心病(coronary heart disease CHD)风险的预测价值。方法 纳入2019年1月至2022年12月于济宁医学院附属医院风湿免疫科住院的确诊为RA的患者,经过纳入和排除后筛选至300例,根据受试者是否患有CHD分为CHD组(102例)与非CHD组(198例),收集相关一般资料及实验室数据,分析其差异性后将差异具有统计学意义的指标纳入logistic回归分析,构建回归模型,观察CRP和TyG指数与RA患者中CHD发生风险的相关性,绘制CRP、TyG指数、CRP联合TyG指数的ROC曲线,报告曲线下面积, 以此评价CRP、TyG指数对RA患者发生CHD的预测价值。结果 两组间CRP、空腹血糖、TyG指数、RA患者年龄、高血压史、糖尿病史差异有统计学意义,logistic回归分析示CRP、TyG指数、高血压史、年龄是RA患者发生CHD的独立危险因素,CRP、TyG指数、二者联合系数的ROC曲线下面积分别为0.608、0.602、0.656。结论 CRP、TyG指数对RA患者发生CHD的风险有良好的预测价值。
中图分类号:
宋怡静, 李健, 宋芹, 邵莉. CRP联合TyG指数对类风湿关节炎患者发生冠心病风险的预测价值[J]. 临床荟萃, 2024, 39(6): 506-511.
Song Yijing, Li Jian, Song Qin, Shao Li. Predictive value of C-reactive protein combined with triglyceride glucose index for coronary heart disease risk in patients with rheumatoid arthritis[J]. Clinical Focus, 2024, 39(6): 506-511.
组别 | 例数 | 性别[例(%)] | 吸烟史[例(%)] | 年龄 (岁) | BMI (kg/m2) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | 有 | 无 | |||||||||||||
非CHD组 | 198 | 67(33.8) | 131(66.2) | 49(24.7) | 149(75.3) | 57.98±11.16 | 22.41(20.55, 24.97) | |||||||||
CHD组 | 102 | 26(25.5) | 76(74.5) | 26(25.5) | 76(74.5) | 68.26±8.73 | 23.71(20.59, 26.51) | |||||||||
统计值 | χ2=2.193 | χ2=0.020 | t=8.760 | Z=-1.606 | ||||||||||||
P值 | 0.139 | 0.888 | <0.01 | 0.108 | ||||||||||||
组别 | 饮酒史[例(%)] | 高血压史[例(%)] | 糖尿病史[例(%)] | |||||||||||||
有 | 无 | 有 | 无 | 有 | 无 | |||||||||||
非CHD组 | 39(19.7) | 159(80.3) | 37(18.7) | 161(81.3) | 14(7.1) | 184(92.9) | ||||||||||
CHD组 | 15(14.7) | 87(85.3) | 53(52.0) | 49(48.0) | 24(23.5) | 78(76.5) | ||||||||||
统计值 | χ2=1.136 | χ2=35.492 | χ2=16.485 | |||||||||||||
P值 | 0.286 | <0.01 | <0.01 |
表1 两组一般资料比较
Tab.1 Comparison of general data between the two groups
组别 | 例数 | 性别[例(%)] | 吸烟史[例(%)] | 年龄 (岁) | BMI (kg/m2) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | 有 | 无 | |||||||||||||
非CHD组 | 198 | 67(33.8) | 131(66.2) | 49(24.7) | 149(75.3) | 57.98±11.16 | 22.41(20.55, 24.97) | |||||||||
CHD组 | 102 | 26(25.5) | 76(74.5) | 26(25.5) | 76(74.5) | 68.26±8.73 | 23.71(20.59, 26.51) | |||||||||
统计值 | χ2=2.193 | χ2=0.020 | t=8.760 | Z=-1.606 | ||||||||||||
P值 | 0.139 | 0.888 | <0.01 | 0.108 | ||||||||||||
组别 | 饮酒史[例(%)] | 高血压史[例(%)] | 糖尿病史[例(%)] | |||||||||||||
有 | 无 | 有 | 无 | 有 | 无 | |||||||||||
非CHD组 | 39(19.7) | 159(80.3) | 37(18.7) | 161(81.3) | 14(7.1) | 184(92.9) | ||||||||||
CHD组 | 15(14.7) | 87(85.3) | 53(52.0) | 49(48.0) | 24(23.5) | 78(76.5) | ||||||||||
统计值 | χ2=1.136 | χ2=35.492 | χ2=16.485 | |||||||||||||
P值 | 0.286 | <0.01 | <0.01 |
组别 | 例数 | CRP(mg/L) | ESR(mm/H) | RF(IU/ml) | TG(mmol/L) | TC(mmol/L) | |||
---|---|---|---|---|---|---|---|---|---|
非CHD组 | 198 | 18.35(5.50, 45.16) | 55.00(27.50, 84.00) | 120.50(44.95, 230.25) | 0.90(0.70,1.23) | 3.92(3.41,4.48) | |||
CHD组 | 102 | 33.64(11.30, 72.70) | 50.50(29.00, 87.25) | 146.60(51.53, 293.38) | 0.95(0.71,1.46) | 3.95(3.21,4.68) | |||
统计值 | Z=-3.050 | Z=-0.474 | Z=-1.231 | Z=-1.614 | Z=-0.414 | ||||
P值 | 0.002 | 0.636 | 0.128 | 0.106 | 0.679 | ||||
组别 | HDL-C(mmol/L) | LDL-C(mmol/L) | FBG(mg/dL) | TyG指数 | |||||
非CHD组 | 1.08(0.92, 1.29) | 2.35(1.97, 2.91) | 88.30(81.09, 101.63) | 8.20(7.94, 8.49) | |||||
CHD组 | 1.15(0.95, 1.31) | 2.42(1.83, 2.81) | 99.11(84.69, 117.13) | 8.37(7.99, 8.82) | |||||
统计值 | Z=-1.175 | Z=-0.525 | Z=-3.304 | Z=-2.895 | |||||
P值 | 0.240 | 0.599 | <0.01 | 0.004 |
表2 两组实验室资料比较
Tab.2 Comparison of laboratory data between the two groups
组别 | 例数 | CRP(mg/L) | ESR(mm/H) | RF(IU/ml) | TG(mmol/L) | TC(mmol/L) | |||
---|---|---|---|---|---|---|---|---|---|
非CHD组 | 198 | 18.35(5.50, 45.16) | 55.00(27.50, 84.00) | 120.50(44.95, 230.25) | 0.90(0.70,1.23) | 3.92(3.41,4.48) | |||
CHD组 | 102 | 33.64(11.30, 72.70) | 50.50(29.00, 87.25) | 146.60(51.53, 293.38) | 0.95(0.71,1.46) | 3.95(3.21,4.68) | |||
统计值 | Z=-3.050 | Z=-0.474 | Z=-1.231 | Z=-1.614 | Z=-0.414 | ||||
P值 | 0.002 | 0.636 | 0.128 | 0.106 | 0.679 | ||||
组别 | HDL-C(mmol/L) | LDL-C(mmol/L) | FBG(mg/dL) | TyG指数 | |||||
非CHD组 | 1.08(0.92, 1.29) | 2.35(1.97, 2.91) | 88.30(81.09, 101.63) | 8.20(7.94, 8.49) | |||||
CHD组 | 1.15(0.95, 1.31) | 2.42(1.83, 2.81) | 99.11(84.69, 117.13) | 8.37(7.99, 8.82) | |||||
统计值 | Z=-1.175 | Z=-0.525 | Z=-3.304 | Z=-2.895 | |||||
P值 | 0.240 | 0.599 | <0.01 | 0.004 |
因素 | 回归系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
高血压史(有/无) | 0.867 | 0.306 | 8.051 | 0.005 | 2.380 | 1.308 | 4.333 |
糖尿病史(有/无) | 0.614 | 0.445 | 1.906 | 0.167 | 1.847 | 0.773 | 4.415 |
CRP(mg/L) | 0.009 | 0.004 | 5.526 | 0.019 | 1.009 | 1.001 | 1.016 |
FBG(mg/dL) | 0.001 | 0.007 | 0.038 | 0.846 | 1.001 | 0.988 | 1.015 |
TyG指数 | 0.827 | 0.363 | 5.178 | 0.023 | 2.286 | 1.122 | 4.660 |
年龄(岁) | 0.087 | 0.016 | 29.144 | <0.01 | 1.091 | 1.057 | 1.126 |
常量 | -13.966 | 3.284 | 18.085 | <0.01 | 0.000 |
表3 多因素logistic回归分析
Tab.3 Multiariable logistic regression analysis
因素 | 回归系数 | 标准误 | Wald χ2值 | P值 | OR值 | 95%CI | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
高血压史(有/无) | 0.867 | 0.306 | 8.051 | 0.005 | 2.380 | 1.308 | 4.333 |
糖尿病史(有/无) | 0.614 | 0.445 | 1.906 | 0.167 | 1.847 | 0.773 | 4.415 |
CRP(mg/L) | 0.009 | 0.004 | 5.526 | 0.019 | 1.009 | 1.001 | 1.016 |
FBG(mg/dL) | 0.001 | 0.007 | 0.038 | 0.846 | 1.001 | 0.988 | 1.015 |
TyG指数 | 0.827 | 0.363 | 5.178 | 0.023 | 2.286 | 1.122 | 4.660 |
年龄(岁) | 0.087 | 0.016 | 29.144 | <0.01 | 1.091 | 1.057 | 1.126 |
常量 | -13.966 | 3.284 | 18.085 | <0.01 | 0.000 |
预测项目 | AUC | 标准误 | P值 | 95%CI | 敏感度 (%) | 特异度 (%) | 约登指数 | 界值 | |
---|---|---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||||
CRP(mg/L) | 0.608 | 0.035 | 0.002 | 0.540 | 0.680 | 61.8 | 58.4 | 0.202 | 25.41 |
TyG指数 | 0.602 | 0.036 | 0.005 | 0.530 | 0.670 | 36.3 | 86.3 | 0.226 | 8.695 |
联合系数 | 0.656 | 0.033 | 0.000 | 0.600 | 0.720 | 51.0 | 74.6 | 0.256 | 0.377 |
表4 CRP、TyG指数、联合系数绘制的ROC曲线所得的各预测值
Tab.4 Each predictive values obtained from ROC curves drawn by CRP, TyG index, and joint coefficient
预测项目 | AUC | 标准误 | P值 | 95%CI | 敏感度 (%) | 特异度 (%) | 约登指数 | 界值 | |
---|---|---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||||
CRP(mg/L) | 0.608 | 0.035 | 0.002 | 0.540 | 0.680 | 61.8 | 58.4 | 0.202 | 25.41 |
TyG指数 | 0.602 | 0.036 | 0.005 | 0.530 | 0.670 | 36.3 | 86.3 | 0.226 | 8.695 |
联合系数 | 0.656 | 0.033 | 0.000 | 0.600 | 0.720 | 51.0 | 74.6 | 0.256 | 0.377 |
组别 | 例数 | CRP(mg/L) | TyG指数 |
---|---|---|---|
CHD+ | 64 | 26.27(8.14,59.78) | 8.36(7.99, 8.81) |
CHD- | 38 | 47.94(21.66,86.26) | 8.49(7.95, 8.90) |
非CHD+ | 176 | 20.36(6.60, 46.25) | 8.20(7.94, 8.47) |
非CHD- | 22 | 14.83(1.26, 23.96) | 8.16(7.89, 8.72) |
统计值 | χ2=16.260 | χ2=8.560 | |
P值 | 0.001 | 0.036 |
表5 调整年龄后CRP、TyG指数在不同亚组间的比较
Tab.5 Comparison of CRP and TyG index between subgroups after adjustment by age
组别 | 例数 | CRP(mg/L) | TyG指数 |
---|---|---|---|
CHD+ | 64 | 26.27(8.14,59.78) | 8.36(7.99, 8.81) |
CHD- | 38 | 47.94(21.66,86.26) | 8.49(7.95, 8.90) |
非CHD+ | 176 | 20.36(6.60, 46.25) | 8.20(7.94, 8.47) |
非CHD- | 22 | 14.83(1.26, 23.96) | 8.16(7.89, 8.72) |
统计值 | χ2=16.260 | χ2=8.560 | |
P值 | 0.001 | 0.036 |
组别 | 例数 | CRP(mg/L) | TyG指数 |
---|---|---|---|
CHD+ | 53 | 28.51(5.82,54.27) | 8.43(8.01, 8.97) |
CHD- | 49 | 37.20(12.20,90.50) | 8.30(7.93, 8.68) |
非CHD+ | 37 | 27.40(13.67, 70.86) | 8.20(7.97, 8.65) |
非CHD- | 161 | 16.77(3.61, 44.08) | 8.19(7.93, 8.46) |
统计值 | χ2=17.170 | χ2=13.320 | |
P值 | <0.01 | 0.004 |
表6 调整高血压史后CRP、TyG指数在不同亚组间的比较
Tab.6 Comparison of CRP and TyG index between subgroups after adjusting by history of hypertension
组别 | 例数 | CRP(mg/L) | TyG指数 |
---|---|---|---|
CHD+ | 53 | 28.51(5.82,54.27) | 8.43(8.01, 8.97) |
CHD- | 49 | 37.20(12.20,90.50) | 8.30(7.93, 8.68) |
非CHD+ | 37 | 27.40(13.67, 70.86) | 8.20(7.97, 8.65) |
非CHD- | 161 | 16.77(3.61, 44.08) | 8.19(7.93, 8.46) |
统计值 | χ2=17.170 | χ2=13.320 | |
P值 | <0.01 | 0.004 |
[1] |
Wang Z, Lan T, Zhang L, et al. Predictive value of the TyG index and rheumatoid factor for cardiovascular disease risk in a rheumatoid arthritis population: Data from a survey of 418 patients[J]. Lipids Health Dis, 2022, 21(1):122.
doi: 10.1186/s12944-022-01735-6 pmid: 36397103 |
[2] |
Contreras-Haro B, Hernandez-Gonzalez SO, Gonzalez-Lopez L, et al. Fasting triglycerides and glucose index: A useful screening test for assessing insulin resistance in patients diagnosed with rheumatoid arthritis and systemic lupus erythematosus[J]. Diabetol Metab Syndr, 2019, 11:95.
doi: 10.1186/s13098-019-0495-x pmid: 31788032 |
[3] |
Zhao J, Fan H, Wang T, et al. TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients[J]. Cardiovasc Diabetol, 2022, 21(1):123.
doi: 10.1186/s12933-022-01548-y pmid: 35778734 |
[4] | Wang Z, Hu K, Wu M, et al. Factors associated with secondary coronary artery disease in rheumatoid arthritis patients: A systematic review and meta-analysis based on observational studies[J]. Musculoskeletal Care, 2023. |
[5] |
Quevedo-Abeledo JC, Rúa-Figueroa Í, Sánchez-Pérez H, et al. Comparable effects of traditional cardiovascular risk factors on subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis[J]. Clin Exp Rheumatol, 2020, 38(5):917-924.
pmid: 31969232 |
[6] | England BR, Thiele GM, Anderson DR, et al. Increased cardiovascular risk in rheumatoid arthritis: Mechanisms and implications[J]. BMJ, 2018, 361:k1036. |
[7] |
Lee TH, Song GG, Choi SJ, et al. Relationship of rheumatoid arthritis and coronary artery disease in the Korean population: A nationwide cross-sectional study[J]. Adv Rheumatol, 2019, 59(1):40.
doi: 10.1186/s42358-019-0084-6 pmid: 31455419 |
[8] | Wang H, Li X, Gong G. Cardiovascular outcomes in patients with co-existing coronary artery disease and rheumatoid arthritis: A systematic review and meta-analysis[J]. Medicine (Baltimore), 2020, 99(14):e19658. |
[9] |
Sengul I, Akcay-Yalbuzdag S, Ince B, et al. Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis[J]. Int J Rheum Dis, 2015, 18(6):640-645.
doi: 10.1111/1756-185X.12695 pmid: 26013310 |
[10] |
Hannawi S, Hannawi H, Al SI. Cardiovascular disease and subclinical atherosclerosis in rheumatoid arthritis[J]. Hypertens Res, 2020, 43(9):982-984.
doi: 10.1038/s41440-020-0483-4 pmid: 32483312 |
[11] | Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities[J]. Semin Arthritis Rheum, 2021, 51(1):219-229. |
[12] | Xu J, Xu W, Chen G, et al. Association of TyG index with prehypertension or hypertension: A retrospective study in Japanese normoglycemia subjects[J]. Front Endocrinol (Lausanne), 2023, 14:1288693. |
[13] | Jian S, Su-Mei N, Xue C, et al. Association and interaction between triglyceride-glucose index and obesity on risk of hypertension in middle-aged and elderly adults[J]. Clin Exp Hypertens, 2017, 39(8):732-739. |
[14] |
Huang Z, Ding X, Yue Q, et al. Triglyceride-glucose index trajectory and stroke incidence in patients with hypertension: A prospective cohort study[J]. Cardiovasc Diabetol, 2022, 21(1):141.
doi: 10.1186/s12933-022-01577-7 pmid: 35897017 |
[15] | Peng N, Kuang M, Peng Y, et al. Associations between TyG-BMI and normal-high blood pressure values and hypertension: Cross-sectional evidence from a non-diabetic population[J]. Front Cardiovasc Med, 2023, 10:1129112. |
[16] |
Zheng R, Mao Y. Triglyceride and glucose (TyG) index as a predictor of incident hypertension: A 9-year longitudinal population-based study[J]. Lipids Health Dis, 2017, 16(1):175.
doi: 10.1186/s12944-017-0562-y pmid: 28903774 |
[17] | Elazab SA, Elsayed WE, Alrahim NM, et al. Relationship between triglyceride-glucose index and disease activity and subclinical atherosclerosis in rheumatoid arthritis[J]. Curr Rheumatol Rev, 2023. |
[18] |
Wang A, Tian X, Zuo Y, et al. Change in triglyceride-glucose index predicts the risk of cardiovascular disease in the general population: A prospective cohort study[J]. Cardiovasc Diabetol, 2021, 20(1):113.
doi: 10.1186/s12933-021-01305-7 pmid: 34039351 |
[19] |
Liang S, Wang C, Zhang J, et al. Triglyceride-glucose index and coronary artery disease: A systematic review and meta-analysis of risk, severity, and prognosis[J]. Cardiovasc Diabetol, 2023, 22(1):170.
doi: 10.1186/s12933-023-01906-4 pmid: 37415168 |
[20] |
Tian X, Zuo Y, Chen S, et al. Distinct triglyceride-glucose trajectories are associated with different risks of incident cardiovascular disease in normal-weight adults[J]. Am Heart J, 2022, 248:63-71.
doi: 10.1016/j.ahj.2022.02.014 pmid: 35248535 |
[21] |
Che B, Zhong C, Zhang R, et al. Triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio as potential cardiovascular disease risk factors: an analysis of UK biobank data[J]. Cardiovasc Diabetol, 2023, 22(1):34.
doi: 10.1186/s12933-023-01762-2 pmid: 36797706 |
[22] | Muhammad IF, Bao X, Nilsson PM, et al. Triglyceride-glucose (TyG) index is a predictor of arterial stiffness, incidence of diabetes, cardiovascular disease, and all-cause and cardiovascular mortality: A longitudinal two-cohort analysis[J]. Front Cardiovasc Med, 2022, 9:1035105. |
[23] |
Fan J, Gao ST, Wang LJ, et al. Association of three simple insulin resistance indexes with prehypertension in normoglycemic subjects[J]. Metab Syndr Relat Disord, 2019, 17(7):374-379.
doi: 10.1089/met.2019.0029 pmid: 31211636 |
[24] |
Yu H, Tao L, Li YG, et al. Association between triglyceride-glucose index trajectories and carotid atherosclerosis progression[J]. Cardiovasc Diabetol, 2023, 22(1):130.
doi: 10.1186/s12933-023-01847-y pmid: 37254140 |
[25] |
Zhang F, Zhang Y, Guo Z, et al. The association of triglyceride and glucose index, and triglyceride to high-density lipoprotein cholesterol ratio with prehypertension and hypertension in normoglycemic subjects: A large cross-sectional population study[J]. J Clin Hypertens (Greenwich), 2021, 23(7):1405-1412.
doi: 10.1111/jch.14305 pmid: 34118112 |
[26] |
Wang X, Xu W, Song Q, et al. Association between the triglyceride-glucose index and severity of coronary artery disease[J]. Cardiovasc Diabetol, 2022, 21(1):168.
doi: 10.1186/s12933-022-01606-5 pmid: 36050734 |
[27] |
Wang J, Huang X, Fu C, et al. Association between triglyceride glucose index, coronary artery calcification and multivessel coronary disease in Chinese patients with acute coronary syndrome[J]. Cardiovasc Diabetol, 2022, 21(1):187.
doi: 10.1186/s12933-022-01615-4 pmid: 36114495 |
[28] | Karpouzas GA, Ormseth SR, Hernandez E, et al. The impact of statins on coronary atherosclerosis progression and long-term cardiovascular disease risk in rheumatoid arthritis[J]. Rheumatology (Oxford), 2022, 61(5):1857-1866. |
[1] | 师丽琪, 雷普文, 钱宝堂. 高强度间歇训练在接受经皮冠状动脉介入治疗冠心病患者心脏康复中的研究进展[J]. 临床荟萃, 2024, 39(5): 466-469. |
[2] | 魏宇涵, 赵亚楠, 张桂彬, 吴雨晴, 董博华, 扈家源, 杨文琦. 单核细胞/高密度脂蛋白胆固醇比值、红细胞分布宽度、尿酸与冠心病患者冠状动脉病变严重程度的相关性[J]. 临床荟萃, 2023, 38(9): 796-801. |
[3] | 李娜娜, 江珊. 血清同型半胱氨酸、胱抑素C、超敏C-反应蛋白水平对急性ST段抬高型心肌梗死患者PCI术后并发心力衰竭的预测价值[J]. 临床荟萃, 2023, 38(2): 121-125. |
[4] | 师佩华, 林彦琳, 毕丽妨. NLR、PLR及MLR与2型糖尿病合并冠心病患者的相关性研究[J]. 临床荟萃, 2023, 38(11): 996-1001. |
[5] | 伊鑫, 刘灿章, 刘强, 王聪, 高腾, 闫杰. 冠心病患者合并焦虑抑郁对冠状动脉斑块成分及性质的影响[J]. 临床荟萃, 2023, 38(1): 50-54. |
[6] | 张上仕, 朱红艳, 李楠, 陈鹰熙. 冠心病合并2型糖尿病患者冠状动脉病变与胰岛素抵抗的相关性分析[J]. 临床荟萃, 2023, 38(1): 46-49. |
[7] | 王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845. |
[8] | 段丽钦. 冠心病患者临床特征、外周微循环状态与冠状动脉病变程度的关系[J]. 临床荟萃, 2022, 37(2): 119-123. |
[9] | 王文琦, 张涛. 司美格鲁肽对2型糖尿病合并冠心病患者心肌缺血总负荷及血清炎症因子的影响[J]. 临床荟萃, 2022, 37(11): 996-1000. |
[10] | 陈曦, 江珊. 中性粒细胞百分比与白蛋白比值与冠状动脉狭窄程度的相关性[J]. 临床荟萃, 2022, 37(1): 26-29. |
[11] | 郭佳敏, 张光明, 杨婧, 谷国强, 卢蕊, 邢航航, 崔炜. 替格瑞洛与氯吡格雷对冠心病患者血管内皮功能的影响[J]. 临床荟萃, 2021, 36(9): 778-781. |
[12] | 尹晓康, 张继平, 朱育刚, 申红霞, 王德峰. 恩格列净对2型糖尿病合并冠心病患者心室重构的影响[J]. 临床荟萃, 2021, 36(8): 713-718. |
[13] | 马飞, 方雪花, 高德全, 张伟. 琥珀酸美托洛尔与曲美他嗪联合应用于冠心病心力衰竭的Meta分析[J]. 临床荟萃, 2021, 36(6): 491-499. |
[14] | 赵伟凤, 马春宇. 25-(OH)D3与冠心病患者冠状动脉狭窄程度的相关性[J]. 临床荟萃, 2021, 36(11): 981-985. |
[15] | 任玲, 江珊. 血清淀粉样蛋白A、高敏C反应蛋白、一氧化氮与稳定型冠心病不良心血管事件的关系[J]. 临床荟萃, 2021, 36(1): 16-20. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||